Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8272763 | 0.88 | MDM2 (0.65) | MDM2TP53 | |
| SCHEMBL4915580 | 0.87 | MDM2 (0.64) | MDM2TP53 | |
| SCHEMBL4915283 | 0.82 | MDM2 (0.67) | MDM2TP53 | |
| SCHEMBL4915296 | 0.82 | MDM2 (0.67) | MDM2TP53 | |
| SCHEMBL4914793 | 0.82 | MDM2 (0.67) | MDM2TP53 | |
| SCHEMBL12083984 | 0.81 | MDM2 (0.88) | MDM2TP53 | |
| SCHEMBL4905909 | 0.81 | MDM2 (0.87) | MDM2TP53 | |
| SCHEMBL4905905 | 0.81 | MDM2 (0.87) | MDM2TP53 | |
| SCHEMBL18568789 | 0.80 | MDM2 (0.82) | MDM2TP53 | |
| SCHEMBL4917328 | 0.79 | MDM2 (0.62) | MDM2TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1786773-B1 | ISOINDOLIN-1-ONE DERIVATIVES | CANCER RES TECH LTD (GB) | 2017-03-01 | — | — | EP | disclosed |
| US-8258175-B2 | Prodrug; novel series of compounds which inhibit the MDM2-p53 interaction and have in vitro activity exerting an anti-tumour effect; cancer | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2012-09-04 | — | — | US | disclosed |
| US-20080261917-A1 | Isoindolin-1-One Derivatives | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2008-10-23 | — | — | US | disclosed |
| EP-1786773-A1 | ISOINDOLIN-1-ONE DERIVATIVES | Cancer Research Technology Limited (GB) | 2007-05-23 | — | — | EP | disclosed |
| WO-2006024837-A1 | ISOINDOLIN-1-ONE DERIVATIVES | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2006-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080261917-A1 | Isoindolin-1-One Derivatives | HCN3, NHERF1, SIGMAR1 | MDM2 1568/4885TP53 2490/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.